Fumaroylamino-4,5-epoxymorphinans and Related Opioids with Irreversible μ Opioid Receptor Antagonist Effects

Journal of Medicinal Chemistry
2012.0

Abstract

We have previously shown that cinnamoyl derivatives of 14β-amino-17-cyclopropylmethyl-7,8-dihydronormorphinone and 7α-aminomethyl-6,14-endoethanonororipavine have pronounced pseudoirreversible μ opioid receptor (MOR) antagonism. The present communication describes the synthesis and evaluation of fumaroylamino analogues of these cinnamoylamino derivatives together with some related fumaroyl derivatives. The predominant activity of the new ligands was MOR antagonism. The fumaroylamino analogues (2a, 5a) of the pseudoirreversible antagonist cinnamoylamino morphinones and oripavines (2b, 5b) were themselves irreversible antagonists in vivo. However the fumaroylamino derivatives had significantly higher MOR efficacy than the cinnamoylamino derivatives in mouse antinociceptive tests. Comparison of 2a and 5a with the prototypic fumaroylamino opioid β-FNA (1a) shows that they have similar MOR irreversible antagonist actions but differ in the nature of their opioid receptor agonist effects; 2a is a predominant MOR agonist and 5a shows no opioid receptor selectivity, whereas the agonist effect of β-FNA is clearly κ opioid receptor (KOR) mediated.

Knowledge Graph

Similar Paper

Fumaroylamino-4,5-epoxymorphinans and Related Opioids with Irreversible μ Opioid Receptor Antagonist Effects
Journal of Medicinal Chemistry 2012.0
14β-O-Cinnamoylnaltrexone and Related Dihydrocodeinones are Mu Opioid Receptor Partial Agonists with Predominant Antagonist Activity
Journal of Medicinal Chemistry 2009.0
Cinnamoyl Derivatives of 7α-Aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7α-Aminomethyl-6,14-endo-ethanotetrahydrooripavine and Related Opioid Ligands
Journal of Medicinal Chemistry 2007.0
Opioid Receptor Modulators with a Cinnamyl Group
Journal of Medicinal Chemistry 2017.0
A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities
Journal of Medicinal Chemistry 1980.0
Structural Determinants of Opioid Activity in Derivatives of 14-Aminomorphinones:  Effect of Substitution in the Aromatic Ring of Cinnamoylaminomorphinones and Codeinones
Journal of Medicinal Chemistry 2006.0
Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 18. N-Substituted 14-Phenylpropyloxymorphinan-6-ones with Unanticipated Agonist Properties:  Extending the Scope of Common Structure−Activity Relationships
Journal of Medicinal Chemistry 2003.0
Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4′-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands
Journal of Medicinal Chemistry 2019.0
Ring constrained analogues of the orvinols: The furanomorphides
Bioorganic & Medicinal Chemistry Letters 1999.0
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different .mu. receptor subtypes in different tissues
Journal of Medicinal Chemistry 1984.0